Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22442278 | 0.83 | MEN1 (0.35) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1579916 | 0.79 | ALDH1A1 (0.35) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1970566 | 0.77 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL4621037 | 0.76 | — | — | |
| SCHEMBL27722393 | 0.76 | — | — | |
| SCHEMBL17460039 | 0.76 | MEN1 (0.32) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL17460038 | 0.76 | MEN1 (0.32) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL22553330 | 0.74 | GABRR1 (0.37) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL22553331 | 0.74 | GABRR1 (0.37) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL17555722 | 0.74 | HIF1A (0.35) | MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842447-B1 | COMPOUND WITH ANTIBIOTIC ACTION | NAICONS S R L (IT) | 2022-08-24 | — | — | EP | claimed |
| EP-3842447-A1 | COMPOUND WITH ANTIBIOTIC ACTION | Naicons S.r.l. (IT) | 2021-06-30 | — | — | EP | claimed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-12-23 | — | — | US | disclosed |
| US-12479846-B2 | EZH2 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-3398947-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-107954999-B | Oxadiazole ring-containing compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-01-12 | — | — | US | disclosed |
| US-20220281872-A1 | EZH2 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2022-09-08 | — | — | US | disclosed |
| EP-1265859-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265860-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-08-15 | — | — | US | disclosed |
| US-6403830-B2 | A S-(2-(1-IMINOETHYL)AMINO)ETHYL)-2-METHYL-L-CYSTEINE AND SALTS | PHARMACIA CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2001072703-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072702-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479846-B2 | EZH2 inhibitor and use thereof | EZH2, BMI1, EZH1 | MEN1 897/4885KMT2A 23/4885HTT 4125/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | MEN1 1351/4885KMT2A 2722/4885HTT 1632/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | MEN1 3749/4885KMT2A 3265/4885HTT 2442/4885 |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | EZH2, BMI1, SUZ12 | MEN1 1801/4885KMT2A 74/4885HTT 1991/4885 |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | MEN1 1353/4885KMT2A 1896/4885HTT 3070/4885 |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | EZH2, BMI1, SUZ12 | MEN1 1801/4885KMT2A 74/4885HTT 1991/4885 |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | MEN1 2096/4885KMT2A 2465/4885HTT 3644/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | MEN1 3842/4885KMT2A 778/4885HTT 182/4885 |
| US-20220281872-A1 | EZH2 INHIBITOR AND USE THEREOF | EZH2, BMI1, EZH1 | MEN1 897/4885KMT2A 23/4885HTT 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.